The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I dose-defining study for MK-2206 combined with gefitinib in NSCLC population enriched with EGFR mutation.
Chia-Chi Lin
No relevant relationships to disclose
Chong-Jen Yu
No relevant relationships to disclose
Chao-Chi Ho
No relevant relationships to disclose
Kuan-Yu Chen
No relevant relationships to disclose
Jin-Yuan Shih
No relevant relationships to disclose
Zhong-Zhe Lin
No relevant relationships to disclose
Yu-lin Lin
No relevant relationships to disclose
Wei-Yu Liao
No relevant relationships to disclose
Shoung-Hui Tsai
No relevant relationships to disclose
Li Yan
Stock Ownership - Merck Sharp & Dohme
James Chih-Hsin Yang
Research Funding - AstraZeneca; Merck Sharp & Dohme